Multivalent vaccine composition with reduced dose of haemophilus influenza type b
CA 2783274 C · Owner: Glaxosmithkline Biologicals S.A. · Inventors: Boutriau, Dominique; Desmons, Pierre Michel; Capiau, Carine
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A multi-valent vaccine composition is described comprising a conjugate of the capsular polysaccharide of H. influenzae b not adsorbed onto an aluminium adjuvant salt and two or more further bacterial polysaccharides. A multi-valent vaccine composition is also described comprising a whole-cell pertussis component tetanus toxoid, diphtheria toxoid, Hepatitis B surface antigen a conjugate of the capsular polysaccharide of H. influenzae b and a conjugate of a capsular polysaccharide of N. meningitidis type A or C (or both). Furthermore a multi-valent vaccine composition is described comprising a whole-cell pertussis component tetanus toxoid, diphtheria toxoid, and a low dose of a conjugate of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 27, 2001 and granted August 7, 2018. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 27, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 27, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.